GILD Gilead Sciences, Inc.

Price (delayed)

$60.67

Market cap

$76.06B

P/E Ratio

N/A

Dividend/share

$2.67

EPS

-$0.23

Enterprise value

$93.42B

Sector: Healthcare
Industry: Drug Manufacturers - General
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firms primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster, CA.

Highlights

Gilead Sciences's debt has decreased by 8% YoY
GILD's EPS has dropped by 106% since the previous quarter and by 105% year-on-year
The company's net income has shrunk by 105% QoQ and by 104% YoY

Key stats

What are the main financial stats of GILD
Market
Shares outstanding
1.25B
Market cap
$76.06B
Enterprise value
$93.42B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.22
Price to sales (P/S)
3.43
EV/EBIT
215.25
EV/EBITDA
51.08
EV/Sales
4.21
Earnings
Revenue
$22.17B
EBIT
$434M
EBITDA
$1.83B
Free cash flow
$8.76B
Per share
EPS
-$0.23
Free cash flow per share
$6.98
Book value per share
$14.37
Revenue per share
$17.67
TBVPS
$30.75
Balance sheet
Total assets
$55.93B
Total liabilities
$37.79B
Debt
$24.1B
Equity
$18.03B
Working capital
$14.08B
Liquidity
Debt to equity
1.34
Current ratio
2.33
Quick ratio
2.09
Net debt/EBITDA
9.49
Margins
EBITDA margin
8.2%
Gross margin
78.6%
Net margin
-1.2%
Operating margin
-4.3%
Efficiency
Return on assets
-0.4%
Return on equity
-1.2%
Return on invested capital
0.9%
Return on capital employed
1%
Return on sales
2%
Dividend
Dividend yield
4.4%
DPS
$2.67
Payout ratio
N/A

GILD stock price

How has the Gilead Sciences stock price performed over time

Financial performance

How have Gilead Sciences's revenue and profit performed over time
Revenue
$22.17B
Gross profit
$17.42B
Operating income
-$961M
Net income
-$257M
Gross margin
78.6%
Net margin
-1.2%
The operating margin has plunged by 122% from the previous quarter and by 111% YoY
The operating income has dropped by 122% since the previous quarter and by 111% year-on-year
Gilead Sciences's net margin has shrunk by 106% QoQ and by 105% YoY
The company's net income has shrunk by 105% QoQ and by 104% YoY

Growth

What is Gilead Sciences's growth rate over time

Valuation

What is Gilead Sciences stock price valuation
P/E
N/A
P/B
4.22
P/S
3.43
EV/EBIT
215.25
EV/EBITDA
51.08
EV/Sales
4.21
GILD's EPS has dropped by 106% since the previous quarter and by 105% year-on-year
Gilead Sciences's equity has decreased by 20% YoY and by 18% from the previous quarter
The stock's price to book (P/B) is 16% less than its 5-year quarterly average of 5.0
GILD's price to sales (P/S) is 12% less than its last 4 quarters average of 3.9 and 10% less than its 5-year quarterly average of 3.8
GILD's revenue is down by 2.4% since the previous quarter

Efficiency

How efficient is Gilead Sciences business performance
The company's return on equity has shrunk by 105% QoQ and by 104% YoY
GILD's return on assets has dropped by 105% since the previous quarter and by 104% year-on-year
Gilead Sciences's ROIC has plunged by 96% YoY and by 93% from the previous quarter
GILD's return on sales has dropped by 95% year-on-year and by 92% since the previous quarter

Dividends

What is GILD's dividend history
DPS
$2.67
Dividend yield
4.4%
Payout ratio
N/A
Recent dividends

Financial health

How did Gilead Sciences financials performed over time
GILD's total assets is 48% higher than its total liabilities
The quick ratio has contracted by 39% YoY and by 25% from the previous quarter
Gilead Sciences's current ratio has decreased by 38% YoY and by 23% QoQ
Gilead Sciences's debt is 34% higher than its equity
The company's debt to equity rose by 23% QoQ and by 17% YoY
Gilead Sciences's equity has decreased by 20% YoY and by 18% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.